CG ONCOLOGY PROVIDES UPDATED TIMELINE FOR PIVOT-006 PHASE 3 TOPLINE DATA IN INTERMEDIATE-RISK NMIBC
CG ONCOLOGY INC - EXPECTS PHASE 3 PIVOT-006 DATA IN 1H 2026
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.